The clinical trial numbers include CTR20182095, CTR20180849, etc. In addition to the antagonist effects on the AR signaling pathway, we also found the inhibitory effects of proxalutamide on glutamine metabolism, redox homeostasis and de novo pyrimidine synthesis in AR-positive PCa cells, resulting in an enhancement in the cellular sensitivity to proxalutamide [18]. Here, AR is linked to posterior cortical atrophy.